Stemline Therapeutics Inc (STML.OQ)
Wed, May 9 2018
* STEMLINE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS
A federal judge has dismissed a lawsuit accusing Stemline Therapeutics Inc of misleading investors about its ability to address the risk of a fatal side effect associated with a drug it was developing to treat certain blood-related cancers.
BRIEF-Stemline Therapeutics Inc - Co Launched An At-Market Offering Of Up To $50 Million Worth Of Shares
* STEMLINE THERAPEUTICS INC - ON MARCH 16, 2018, CO LAUNCHED AN AT--MARKET OFFERING OF UP TO $50 MILLION WORTH OF SHARES OF COMPANY'S COMMON STOCK Source text (http://bit.ly/2HHHaYN) Further company coverage: (Reuters.Brief@thomsonreuters.com)
* STEMLINE THERAPEUTICS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS
- How Stemline's Latest Catalyst Shifts The Investment Thesis
- Your Daily Pharma Scoop: Redhill Receives NoA, Regeneron Gets CRL, Stemline NDA Under Review
- 3 Things In Biotech, August 14: Is Stemline Finally A Go In Cancer?
- Playing The Expectations Game In Biotech
- 3 Things In Biotech, June 17: Ruxolitinib Climbs Higher
- A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals